Stereotaxis (STXS) 10-K 20 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Mar. 13, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Stereotaxis, Inc.
Entity Filer Category	Smaller Reporting Company
Entity Central Index Key	1,289,340
Trading Symbol	stxs
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Amendment Flag	false
Document Type	10-K
Document Fiscal Period Focus	FY
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		58,865,036
Entity Public Float			$ 11.2

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 3,686,302	$ 8,501,392
Accounts receivable, net of allowance of $361,350 and $379,817 in 2017 and 2016, respectively	4,287,255	4,665,959
Inventories, net	1,146,971	5,381,103
Prepaid expenses and other current assets	750,085	855,295
Total current assets	9,870,613	19,403,749
Property and equipment, net	592,688	1,086,244
Intangible assets, net	159,470	436,569
Other assets	44,432	39,241
Total assets	10,667,203	20,965,803
Current liabilities:
Accounts payable	1,654,101	2,623,010
Accrued liabilities	3,195,247	4,491,164
Deferred revenue	5,702,769	8,751,336
Warrants	19,574,977	19,787,007
Total current liabilities	30,127,094	35,652,517
Long-term deferred revenue	611,863	522,329
Other liabilities	535,369	320,409
Total liabilities	31,274,326	36,495,255
Convertible Preferred stock:
Convertible Preferred stock, par value $0.001; 10,000,000 shares authorized, 23,900 shares outstanding at 2017 and 2016	5,960,475	5,960,475
Stockholders' deficit:
Common stock, par value $0.001; 300,000,000 shares authorized, 22,805,731 and 22,063,582 shares issued at 2017 and 2016, respectively	22,806	22,064
Additional paid in capital	450,748,403	449,939,406
Treasury stock, 4,015 shares at 2017 and 2016	(205,999)	(205,999)
Accumulated deficit	(477,132,808)	(471,245,398)
Total stockholders' deficit	(26,567,598)	(21,489,927)
Total liabilities and stockholders' deficit	$ 10,667,203	$ 20,965,803

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Balance Sheets [Abstract]
Accounts receivable, allowance	$ 361,350	$ 379,817
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	23,900	23,900
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	22,805,731	22,063,582
Treasury stock, shares	4,015	4,015

Statements Of Operations

Statements Of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue:
Systems	$ 4,275,798	$ 5,776,843
Disposables, service and accessories	26,868,302	26,387,273
Total revenue	31,144,100	32,164,116
Cost of revenue:
Systems	6,199,643	3,660,012
Disposables, service and accessories	4,554,596	3,869,321
Total cost of revenue	10,754,239	7,529,333
Gross margin	20,389,861	24,634,783
Operating expenses:
Research and development	4,760,806	5,487,609
Sales and marketing	13,039,499	15,228,193
General and administrative	8,509,153	10,345,338
Total operating expenses	26,309,458	31,061,140
Operating loss	(5,919,597)	(6,426,357)
Other income (expense)	212,031	(2,009,150)
Interest expense (net)	(179,844)	(2,483,384)
Gain on extinguishment of debt		5,632,171
Net loss	(5,887,410)	(5,286,720)
Deemed dividend on convertible preferred stock		(6,145,402)
Cumulative dividend on convertible preferred stock	(1,432,259)	(368,152)
Net loss attributable to common stockholders	$ (7,319,669)	$ (11,800,274)
Net loss per share attributable to common stockholders:
Basic	$ (0.32)	$ (0.54)
Diluted	$ (0.32)	$ (0.54)
Weighted average number of common shares and equivalents:
Basic	22,614,248	21,807,634
Diluted	22,614,248	21,807,634

Statements Of Convertible Prefe

Statements Of Convertible Preferred Stock And Stockholders' Equity - USD ($)	Common Stock [Member]	Convertible Preferred Stock [Member]	Additional Paid-In Capital [Member]Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Common Stock [Member]	Total
Balance, Amount at Dec. 31, 2015	$ 21,551			$ 448,517,472	$ (205,999)	$ (465,958,678)		$ (17,625,654)
Balance, Shares at Dec. 31, 2015	21,551,173
Issuance of common stock			$ (1,464)				$ (1,464)
Issuance of stock, Amount		$ 5,986,081
Issuance of stock, Shares		24,000
Share-based compensation				1,365,121				1,365,121
Restricted stock vestings, Amount	$ 318			(318)
Restricted stock vestings, Shares	317,962
Net loss						(5,286,720)		(5,286,720)
Employee stock purchase plan, Amount	$ 39			33,145				33,184
Employee stock purchase plan, Shares	39,008
Beneficial conversion feature of Convertible Preferred Stock		$ (6,145,402)		6,145,402				6,145,402
Deemed dividend related to beneficial conversion feature of Convertible Preferred Stock		6,145,402		(6,145,402)				(6,145,402)
Conversion of Convertible Preferred Stock, Amount	$ 156	$ (25,606)		25,450				25,606
Conversion of Convertible Preferred Stock, Shares	155,439	(100)
Balance, Amount at Dec. 31, 2016	$ 22,064	$ 5,960,475		449,939,406	(205,999)	(471,245,398)		(21,489,927)
Balance, Shares at Dec. 31, 2016	22,063,582	23,900
Share-based compensation				768,682				768,682
Restricted stock vestings, Amount	$ 675			(552)				123
Restricted stock vestings, Shares	675,473
Net loss						(5,887,410)		(5,887,410)
Employee stock purchase plan, Amount	$ 67			40,867				40,934
Employee stock purchase plan, Shares	66,676
Deemed dividend related to beneficial conversion feature of Convertible Preferred Stock								(6,100,000)
Balance, Amount at Dec. 31, 2017	$ 22,806	$ 5,960,475		$ 450,748,403	$ (205,999)	$ (477,132,808)		$ (26,567,598)
Balance, Shares at Dec. 31, 2017	22,805,731	23,900

Statements Of Convertible Pref6

Statements Of Convertible Preferred Stock And Stockholders' Equity (Parenthetical) - Convertible Preferred Stock [Member]	12 Months Ended
	Dec. 31, 2016USD ($)
Preferred stock, discount	$ 17,649,231
Stock issuance costs	$ 159,322

Statements Of Cash Flows

Statements Of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net loss	$ (5,887,410)	$ (5,286,720)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	554,361	367,611
Amortization of intangibles	199,321	199,320
Amortization of deferred finance costs	99,998	188,239
Share-based compensation	768,682	1,365,121
Gain on debt extinguishment		(5,632,171)
Noncash interest		485,857
Loss on asset disposal	98,550
Adjustment of warrants	(212,030)	2,009,150
Provisions for obsolete inventory	3,948,726	283,441
Changes in operating assets and liabilities:
Accounts receivable	378,704	1,710,511
Inventories	285,406	(1,136,612)
Prepaid expenses and other current assets	105,215	(187,940)
Other assets	(5,191)	(7,548)
Accounts payable	(968,909)	782,875
Accrued liabilities	(1,295,917)	(1,567,226)
Deferred revenue	(2,959,033)	(181,468)
Other liabilities	214,960	44,806
Net cash used in operating activities	(4,674,567)	(6,562,754)
Cash flows from investing activities
Purchase of fixed assets	(81,577)	(410,184)
Net cash used in investing activities	(81,577)	(410,184)
Cash flows from financing activities
Payments of deferred financing costs	(100,000)	(100,000)
Proceeds from revolving line of credit		7,650,000
Payments of revolving line of credit		(7,650,000)
Payments of Healthcare Royalty Partners debt		(13,020,780)
Proceeds from issuance of stock, net of issuance costs	41,054	23,001,528
Net cash provided by (used in) financing activities	(58,946)	9,880,748
Net increase (decrease) in cash and cash equivalents	(4,815,090)	2,907,810
Cash and cash equivalents at beginning of period	8,501,392	5,593,582
Cash and cash equivalents at end of period	$ 3,686,302	8,501,392
Supplemental disclosures of cash flow information:
Interest paid		$ 2,251,613

Description Of Business

Description Of Business	12 Months Ended
	Dec. 31, 2017
Description Of Business [Abstract]
Description Of Business	1. Description of Business Stereotaxis designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional, procedures. The Epoch Solution is comprised of the Niobe ES Remote Magnetic Navigation System (“ Niobe ES system”), Odyssey Information Management Solution (“ Odyssey Solution”), and the Vdrive Robotic Navigation System (“ Vdrive system ”), and related devices. The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter resulting in improved navigation, efficient procedures and reduced x- ray e xposure. As of December 31, 2017 , the Company had an installed base of 128 Niobe ES systems. In addition to the Niobe system and its components, Stereotaxis also has developed the Odyssey Solution, which consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called Odyssey Cinema , which is an innovative solution delivering synchronized content for optimized workflow, advanced care and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation and training. Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the Niobe ES system control of therapeutic catheters for fully remote procedures and enables single-operator workflow and is sold as two options, the Vdrive system and the Vdrive Duo system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems. We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and software licenses. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion. The core components of Stereot axis systems, such as Niobe system, Odyssey Solution, Cardiodrive and various disposable interventional devices have received regulatory clearance in the U.S., Europe, Canada, China, Japan and various other countries. We have received the regulatory clearance, licensing and/or CE Mark approvals that allow us to market the Vdrive and Vdrive Duo systems with the V-CAS , V-Loop and V-Sono devices in the U.S., Canada and European Union . The V-CAS Deflect catheter advancement system has been CE Marked for sale in the European Union. 

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The Company believes the cash on hand at December 31, 2017 plus the $10 million of proceeds from the March 2018 financing will be sufficient to meet its obligations as they become due in the ordinary course of business for at least 12 months following the date these financial statements are issued. The Company has sustained operating losses throughout its corporate history and expects that its 2018 expenses will exceed its 2018 gross margin. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations or expense reductions are in place. The Company’s liquidity needs will be largely determined by the success of clinical adoption within the installed base of Niobe systems as well as by new placements of capital systems. The Company also may consider raising cash through capital transactions, which could include either debt or equity financing.  Cash and Cash Equivalents The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. No cash was restricted at December 31, 2017 or 2016. Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators. Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 12 for disclosure of fair value measurements.  Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items. Property and Equipment Property and equipment consist primarily of leasehold improvements, computer, office, research and demonstration equipment, and equipment held for lease and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years. Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs . Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10 - 15 years. If facts and circumstances suggest that an intangible asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs . Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates. Revenue and Costs of Revenue The Company recognizes revenue based on the Multiple-Deliverable Revenue Arrangements guidance (“ASU 2009-13”). ASU 2009-13 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimis effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred. Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts rec eivable from strategic relationships under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables at December 31, 2017 or 2016 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned. Share-Based Compensation Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is remeasured on a quarterly basis through the vesting or forfeiture date. The Company utilized the Black-Scholes valuation model to determine the fair value of share-based payments at the date of previously issued grant using risk-free interest rate based on the Treasury yield on the date of the grant and expected volatility based on the Company’s historical volatility over the expected term of the option. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Restricted shares and units granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments. Shares purchased by employees under the 2009 Employee Stock Purchase Plan are considered to be non-compensatory. Net Earnings (Loss) per Common Share Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our Convertible Preferred Stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our Convertible Preferred Stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, warrants, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our Convertible Preferred Stock issued and outstanding during the period, except where the effect of such securities would be antidilutive . The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights, warrants or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. As of December 31, 2017, the Company had 413,301 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $9.04 per share, 38,779,119 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $0.82 per share, and 39,537,501 shares of our common stock issuable upon conversion of our Series A Convertible Preferred Stock. The Company had no unearned restricted shares outstanding for the period ended December 31, 2017. Income Taxes In accordance with general accounting principles for income taxes , a deferred income tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized. Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate. Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. Concentrations of Risk The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of government provided insurance on such deposits. Revenue from Biosense Webster Inc. related to royalties and Odyssey system sales accounted for $3,304,126 and $4,099,075 or 11% , and 13% , of total net revenue for the years ended December 31, 2017, and 2016, respectively. No other single customer accounted for more than 10% of total revenue for the year ended December 31, 2017.  Reclassifications Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses. Recently Issued Accounting Pronouncements  In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” This amendment is intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, forfeitures, and classification on the statement of cash flows. This update was effective for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company) and interim periods within those fiscal years, with earlier application permitted. The Company adopted this guidance in the first quarter of 2017. The adoption of ASU 2016-09 did not materially impact the Company’s consolidated financial position, results of operations, equity, or cash flows.  In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” regarding the subsequent measurement of inventory as part of its Simplification Initiative. This standard was effective for public companies for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company), including interim periods within those fiscal years. This Update should be applied prospectively, and early application is permitted as of the beginning of an interim or annual reporting period. The Company adopted this accounting standard update in the first quarter of 2017. The adoption of ASU 2015-11 did not materially impact the company’s results of operations, financial conditions, cash flows, or financial statement presentation.  In November 2015, the FASB issued Accounting Standards Update (“ASU” or “Update”) No. 2015-17, “Income Taxes (Topic 740): To simplify the presentation of deferred income taxes.” The amendments in this Update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. This standard is effective for public companies for financial statements issued for annual periods beginning after December 15, 2016 (January 1, 2017 for the Company), and interim periods within those annual periods. We have adopted this accounting standard update and there was no impact to the results of operations or cash flows  In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02 - Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update.  In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists or when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter of 2017 (December 31, 2016 for the Company). We have adopted this accounting standard update and provided the relevant disclosures in Note 1. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers," which converges the FASB's and the International Accounting Standards Board's current standards on revenue recognition. The standard provides companies with a single model to use in accounting for revenue arising from contracts with customers and supersedes current revenue guidance. The core principle of the ASU is that an entity should recognize revenue for the transfer of goods or services equal to the amount that it expects to be entitled to receive for those goods or services. ASU 2014-09 requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments. The standard is effective for annual and interim periods beginning after December 15, 2017 (January 1, 2018 for the Company). Early adoption is not permitted. The standard permits companies to either apply the adoption to all periods presented, or apply the requirements in the year of adoption through a cumulative adjustment. The Company will adopt ASU 2014-09 during the first quarter of 2018 using the modified retrospective method. We are substantially complete with our evaluation of the impact of adopting ASU 2014-09 on our consolidated financial statements, and we do not expect significant changes in the timing or method of revenue recognition for any of our material revenue streams. In connection with adopting ASU 2014-09, we expect to record a cumulative-effect reduction to accumulated deficit of $0.4 million on January 1, 2018. This adjustment primarily relates to the deferral of costs to obtain a contract that were previously expensed at the beginning of the contract period .

Inventory

Inventory	12 Months Ended
	Dec. 31, 2017
Inventory [Abstract]
Inventory	3. Inventory Inventory consists of the following:    December 31, 2017 December 31, 2016   Raw materials $ 2,528,270 $ 2,397,430  Work in process 4,836 341,125  Finished goods 2,515,637 2,915,162  Reserve for obsolescence (3,901,772) (272,614)  Total inventory $ 1,146,971 $ 5,381,103 

Prepaid Expenses And Other Curr

Prepaid Expenses And Other Current Assets	12 Months Ended
	Dec. 31, 2017
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid Expenses And Other Current Assets	4. Prepaid Expenses and Other Current Assets  Prepaid expenses and other current assets consist of the following:      December 31, 2017 December 31, 2016   Prepaid expenses $ 575,501 $ 575,886  Deferred financing costs 24,658 24,658  Deposits 194,358 293,992  Total prepaid expenses and other assets 794,517 894,536  Less: Noncurrent prepaid expenses and other assets (44,432) (39,241)  Total current prepaid expenses and other assets $ 750,085 $ 855,295 

Property And Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2017
Property And Equipment [Abstract]
Property And Equipment	5. Property and Equipment Property and equipment consist of the following:    December 31, December 31,  2017 2016   Equipment $ 7,295,698 $ 8,397,528  Equipment held for lease - 303,412  Leasehold improvements 2,592,339 2,719,860  9,888,037 11,420,800  Less: Accumulated depreciation (9,295,349) (10,334,556)  Net property and equipment $ 592,688 $ 1,086,244 

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2017
Intangible Assets [Abstract]
Intangible Assets	6. Intangible Assets  As of December 31, 2017 and 2016, the Company had total intangible assets of $ 3,143,291 and $3, 221,069 , respectively. Accumulated amortization at December 31, 2017 and 2016 was $2,983,821 and $2,784,500 , respectively. Amortization expense for the years 2017 and 2016 was $199,321 and $199,32 0 , respectively, as determined under the straight-line method. The estimated future amortization of intangible assets is $65,988 in 2018, $65,988 in 2019 and $27,495 through May 2020. During the fourth quarter of 2017, the Company also recognized impairment charges of $77,778 in research and development expense for certain intellectual property rights relating to the Company’s Niobe ES system. The impairment is the result of an analysis that indicated it was probable the undiscounted future cash flows produced by the intellectual property would not exceed its book value during the remaining six months of its useful life. 

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2017
Accrued Liabilities [Abstract]
Accrued Liabilities	7. Accrued Liabilities Accrued liabilities consist of the following:    December 31, December 31,  2017 2016   Accrued salaries, bonus, and benefits $ 1,641,491 $ 2,452,183  Accrued rent 441,417 965,412  Accrued licenses and maintenance fees 581,672 561,450  Accrued warranties 164,365 222,845  Accrued taxes 234,668 219,017  Accrued professional services 367,072 180,450  Other 299,931 210,216  Total accrued liabilities 3,730,616 4,811,573  Less: Long term accrued liabilities (535,369) (320,409)  Total current accrued liabilities $ 3,195,247 $ 4,491,164 

Deferred Revenue

Deferred Revenue	12 Months Ended
	Dec. 31, 2017
Deferred Revenue [Abstract]
Deferred Revenue	8. Deferred Revenue Deferred revenue consists of the following:    December 31, December 31,  2017 2016   Product shipped, revenue deferred $ 941,724 $ 549,709  Customer deposits - 2,910,000  Deferred service and license fees 5,372,908 5,813,956  Total deferred revenue 6,314,632 9,273,665  Less: Long-term deferred revenue (611,863) (522,329)  Total current deferred revenue $ 5,702,769 $ 8,751,336 

Long-Term Debt And Credit Facil

Long-Term Debt And Credit Facilities	12 Months Ended
	Dec. 31, 2017
Long-Term Debt And Credit Facilities [Abstract]
Long-Term Debt And Credit Facilities	9. Long-Term Debt and Credit Facilities As of December 31, 2017 and 2016, there were no contractual principal maturities of debt. The revolving line of credit is secured by substantially all of the Company’s assets. The Company is required under the Credit Agreements to maintain its primary operating account and the majority of its cash and investment balances in accounts with the primary lender . Revolving line of credit The Company has had a working capital line of credit with its primary lender, Silicon Valley Bank, since 2004. The revolving line of credit is secured by substantially all of the Company’s assets. The maximum available under the line is $5.0 million subject to the value of collateralized assets. The Company is required under the revolving line of credit to maintain its primary operating account and the majority of its cash and investment balances in accounts with its primary lender. The facility was amended on March 27, 2015, extending the maturity date to March 31, 2018. On May 10, 2016, the Company and the primary lender agreed to modify certain financial covenants, and on November 7, 2017 to adjust the maximum availability under the Company’s revolving line of credit from $10.0 million to $5.0 million with a pro-rata reduction in related loan costs, as well as a reduction in the interest rate floor from 7.0% to 5.75% . The current agreement requires the Company to maintain a liquidity ratio greater than 1.50:1 .00, excluding certain short term advances from the calculation, and a minimum tangible net worth of not less than (no worse than) negative $24.0 million for the quarters ended June 30, 2016, September 30, 2016, December 31, 2016, March 31, 2017, June 30, 2017, and September 30, 2017; and not less than (no worse than) negative $24.5 million for the quarters ended December 31, 2017 and March 31, 2018. As of December 31, 2017 , the Company had no outstanding debt under the revolving line of credit. Draws on the line of credit are made based on the borrowing capacity one week in arrears. As of D ecember 31, 2017 the Company had a borrowing capacity of $2. 7 million based on the Co mpany’s collateralized assets. The Company’s total liquidity as of December 31, 2017, was $ 6.4 million, which included cash and cash equivalents of $ 3.7 million. As of December 31, 2017 , we were in compliance with all financial covenants of this agreement and we anticipate continued compliance throughout the remainder of 2018. Healthcare Royalty Partners Debt In November 2011, the Company entered into a loan agreement with Healthcare Royalty Partners (formerly “Cowen Healthcare Royalty Partners II, L.P.”). Under the agreement the Company borrowed from Healthcare Royalty Partners $15 million. The Company was permitted to borrow up to an additional $5 million in the aggregate based on the achievement by the Company of certain milestones related to Niobe system sales in 2012. On August 8, 2012, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the nine months ended June 30, 2012. On January 31, 2013, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the twelve months ended Dece mber 31, 2012. The loan was to be repaid through, and secured by, royalties payable to the Company under its Development, Alliance and Supply Agreement with Biosense Webster, Inc. The Biosense Agreement relates to the development and distribution of magnetically enabled catheters used with Stereotaxis' Niobe system in cardiac ablation procedures. Under the terms of the Agreement, Healthcare Royalty Partners was entitled to receive 100% of all royalties due to the Company under the Biosense Agreement until the loan was repaid. The loan was a full recourse loan, scheduled to mature on December 31, 2018 , and bore interest at an annual rate of 16% payable quarterly with royalties received under the Biosense Agreement. If the payments received by the Company under the Biosense Agreement were insufficient to pay all amounts of interest due on the loan, then such deficiency would have increased the outstanding principal amount on the loan. The loan was also secured by certain assets and intellectual property of the Company. The agreement also contained customary affirmative and negative covenants. The use of payments due to the Company under the Biosense Agreement was approved by our primary lender In September 2016, the Company extinguished the remainder of the debt of $18.1 million, net of deferred financing costs of approximately $0.3 million, as well as accrued interest of $0.5 million for $13.0 million based upon an agreement entered into with Healthcare Royalty Partners. Following the repayment of the loan obligation, the royalties under the Biosense Agreement are now paid to the Company. As a result of the debt extinguishment, the C ompany recognized a net gain of $5.6 million in 2016.

Lease Obligations

Lease Obligations	12 Months Ended
	Dec. 31, 2017
Lease Obligations [Abstract]
Lease Obligations	10. Lease Obligations  The Company leases its facilities under operating leases. For the years ended December 31, 201 7 and 2016 rent expense was $588,197 and $1,187,989 , respectively. The rent expense for the years ended December 31 , 201 7 and 2016 is net of sublease income of $8 12,660 and $91,579 , respectively.  In January 2006, the Company moved its primary operations into its current facilities. The facility is subject to a lease which expires in December 31, 2018. Under the terms of th e lease, the Company has an option to renew for up to three additional years. The lease contains an escalating rent provision which the Company has straight-lined over the term of the lease.  In the third quarter of 2013, the Company modified the existing lease agreement to terminate approximately 13,000 square feet of unimproved space. The costs associated with the termination were $515,138 , and were accrued as a rent liability as of September 3 0, 2013. As of December 31, 2017 , the remaining accrued costs associated with the termination were $95,455 .  Between the fourth quarter of 2015 and July, 2016, the Company sublet 3,152 square feet of the first floor office space.  In August 2016, the Company entered into an agreement to sublease approximately 11,000 square feet of office space immediately and an additional 16,000 square feet of office space beginning in January of 2017, with the term of the sublease ending on December 31, 2018 . As of December 31, 2017, the remaining accrued costs associated with the termination were $26,202 .  The future minimum lease payments under non-cancelable leases as of December 31, 201 7 are as follows (excluding sublease income) :     Year Operating Lease Payments  2018 $ 2,067,392  2019 11,497  2020 8,622  Total minimum lease payments 2,087,511  Less amounts representing sublease receipts (764,917)  $ 1,322,594 

Convertible Preferred Stock And

Convertible Preferred Stock And Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Convertible Preferred Stock And Stockholders' Equity [Abstract]
Convertible Preferred Stock And Stockholders' Equity	11. Convertible Preferred Stock and Stockholders’ Equity The holders of common stock are entitled one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the prior rights of holders of all classes of stock having priority rights as dividends and the conditions of the Revolving Credit Agreement. No dividends have been declared or paid as of December 31, 2017 . Convertible Preferred Stock and Warrants On September 26, 2016, the Company entered into a Securities Purchase Agreement with certain institutional and other accredited investors whereby it agreed to sell, for an aggregate purchase price of $24.0 million, (i) an aggregate of 24,000 shares of Series A Convertible Preferred Stock, par value $0.001 with a stated value of $1,000 per share which are convertible into shares of the Company’s common stock and (ii) warrants to purchase an aggregate of 36,923,078 shares of common stock. The transaction closed on September 29, 2016. The Company received net proceeds from the sale of the convertible preferred stock and warrants of $23.0 million, after offering expenses. The Company used $13.0 million of the funds to satisfy in full all amounts outstanding under the Loan Agreement with Healthcare Royalty Partners, as noted above, and the remaining proceeds were used for general corporate purposes. The designations, preferences, powers and rights of the convertible preferred shares are set forth in a Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock (“Certificate of Designations”) filed with the Delaware Secretary of State. The convertible preferred shares are entitled to vote on an as-converted basis with the common stock, subject to specified beneficial ownership issuance limitations. The convertible preferred shares bear dividends at a rate of six percent ( 6% ) per annum, which are cumulative and accrue daily from the date of issuance on the $1,000 stated value. Such dividends will not be paid in cash except in connection with any liquidation, dissolution or winding up of the Company or any redemption of the convertible preferred shares. Instead the value of the accrued dividends is added to the liquidation preference of the convertible preferred shares and will increase the number of shares of common stock issuable upon conversion. Each convertible preferred share is convertible at the option of the holder from and after the date of issuance with no expiration date, at an initial conversion price of $0.65 per share, subject to adjustment in the event of stock splits, dividends, mergers, sales of all or substantially all of our assets or similar transactions, subject to specified beneficial ownership issuance limitations. Each holder of convertible preferred shares has the right to require us to redeem such holder’s convertible preferred shares upon the occurrence of specified events, which include certain business combinations, the sale of all or substantially all of the Company’s assets or the sale of more than 50% of the outstanding shares of the Company’s common stock. In addition, the Company has the right to redeem the convertible preferred shares in the event of a change of control as defined in the Certificate of Designations. The convertible preferred shares rank senior to our common stock as to distributions and payments upon the liquidation, dissolution and winding up of the Company. No such distributions or payments upon the liquidation, dissolution and winding up of the Company may be made to the holders of common stock unless and until the holders of convertible preferred shares have received the stated value of $1,000 per share plus any accrued and unpaid dividends. Until all convertible preferred shares have been converted or redeemed, no dividends may be paid on the common stock without the express written consent of the holders of a majority of the outstanding convertible preferred shares. In the event that dividends or other distributions of assets are made or paid by the Company to the holders of the common stock, the holders o f convertible preferred shares are entitled to participate in such dividend or distribution on an as-converted basis. On the date of the issuance, the fair value of the convertible preferred stock was greater than the allocated proceeds received for the Series A convertible preferred stock. As such, the Company accounted for the beneficial conversion feature under ASC 470-20, Debt with Conversion feature under ASC 470-20, Debt with Conversion and Other Options. The Company recorded a deemed dividend charge of $6.1 million for the accretion of a discount on the Series A convertible preferred stock. The deemed dividend was a non-cash transaction and is reflected below net loss to arrive at net loss available to common stockholders. Since the convertible preferred shares are subject to conditions for redemption that are outside the Company’s control, the convertible preferred shares are presently reported in the mezzanine section of the balance sheet. The warrants issued in conjunction with the convertible preferred stock have an exercise price equal to $0.70 per share subject to adjustments as provided under the terms of the warrants. The warrants are exercisable through September 29, 2021, subject to specified beneficial ownership issuance limitations. The warrants may be exercised by any holder on a cashless basis if, at any time after the date that is 180 days after the closing, the registration statement required by the Registration Rights Agreement described below is not effective and available for resale of all of the shares of common stock issuable upon exercise of such holder’s warrants. Due t o the fact that the warrants were puttable upon the occurrence of certain events outside of the Company’s control prior to being amended in February 2018, the warrants qualified as liabilities under ASC 480-10 as of December 31, 2017 . The calculat ed fair value of the warrants was classified as a liability and was periodically re-measured with any changes in value recognized in “Other income (expense)” in the Statements of Operations. See Note 1 2 for additional details. On December 2, 2016, 100 shares of convertible preferred stock plus accumulated dividends were converted into 155,439 common shares. On February 28, 2018, the Company entered into a Consent and Amendment with the holders of a majority of the shares of common stock issuable upon exercise of the outstanding warrants (the “SPA Warrants”) issued pursuant to the Stock Purchase Agreement d ated September 26, 2016. The Consent and Amendment amended and restated the SPA Warrants providing for a reduction in the exercise price of the SPA Warrants from $0.70 per share to $0.28 per share for a period between March 1, 2018 and March 5, 2018 to encourage early exercise. Among other changes, the Consent and Amendment modified the beneficial ownership limitation related to the warrants and eliminated the right of holders to require the Company to redeem their SPA Warrants in exchange for cash in certain circumstances which required liability accounting for the warrants on the balance sheet. During the restricted exercise period, Stereotaxis received exercise notices for 35,791,927 warrants. Refer to Note 20 for discussion of subsequent events . Listing Transfer to OTCQX ® Best Market On August 2, 2016, the Company received a determination letter from the Nasdaq Hearings Panel (the “Panel”) notifying the Company that its common stock would be delisted from The Nasdaq Capital Market (“Nasdaq”) and that suspension of trading in the shares would be effective at the open of business on August 4, 2016. The delisting was completed by the filing of a Form 25 Notification of Delisting with the Securities Exchange Commission on November 10, 2016. The Panel made the determination to delist the Company’s common stock because the Company did not demonstrate compliance with the minimum $35 million market value of listed securities requirement for a period of ten consecutive trading days by August 1, 2016, as required by a decision previously issued by the Panel on May 2, 2016. The Company’s shares of common stock commenced trading on the OTCQX ® Best Market on August 4, 2016 under the Company’s current ticker symbol of “STXS.”  Controlled Equity Offering The Company entered into a Controlled Equity Offering SM sales agreement (the “Sales Agreement”) in May 2014, as amended on March 26, 2015, with Cantor Fitzgerald & Co. (“Cantor”), as agent and/or principal, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate gross sales price of up to $18.0 million. The Company paid Cantor a commission of 3.0% of the gross proceeds from any common stock sold through the Sales Agreement. There were no proceeds from the Controlled Equity Offering during the twelve months ended December 31, 2016. The Sales Agreement expired in November 2016 upon the expiration of our Registration Statement on Form S-3. The Company has reserved shares of common stock for conversion of convertible preferred stock, exercise of warrants, and the issuance of options granted under the Company’s stock option plan and its stock purchase plan as follows:      December 31, December 31,  2017 2016  Warrants 38,779,119 38,963,443  Series A Convertible Preferred Stock Series 47,844,562 47,844,562  Stock award plans 5,573,046 1,524,996  Employee Stock Purchase Plan 125,618 192,290  92,322,345 88,525,291  Refer to Note 20 for discussion of subsequent events. Stock Award Plans The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In August 2012, the Board of Directors adopted a stock incentive plan (the 2012 Stock Incentive Plan) which was subsequently approved by the Company’s stockholders. This plan replaces the 2002 Stock Incentive Plan which expired on March 25, 2012. The 2012 Stock Incentive Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted shares and restricted share units to employees, directors, and consultants. Options granted under the 2012 Stock Incentive Plan expire no later than ten years from the date of grant. The exercise price of each incentive stock option shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. The vesting provisions of individual options may vary, but incentive stock options generally vest 25% on the first anniversary of each grant and 1/48 per month over the next three years. Stock appreciation rights are rights to acquire a calculated number of shares of the Company’s common stock upon exercise of the rights. The number of shares to be issued is calculated as the difference between the exercise price of the right and the aggregate market value of the underlying shares on the exercise date divided by the market value as of the exercise date. Stock appreciation rights granted under the 2012 Stock Incentive Plan generally vest 25% on the first anniversary of such grant and 1/48 per month over the next three years and expire no later than ten years from the date of grant. The Company generally issues new shares upon the exercise of stock options and stock appreciation rights.  Restricted share grants are either time-based or performance-based. Time-based restricted shares generally cliff vest three years after grant. Performance-based restricted shares vest upon the achievement of performance objectives which are determined by the Company’s Board of Directors. Restricted stock unit grants are time-based and generally vest over a period of four years. Options granted to non-employee directors expire no later than ten years from the date of grant. The exercise price of options to non-employee directors shall not be less than 100% of the fair value of the stock subject to the option on the date the option is gr anted. Initial grants of equity awards to new directors generally vest over a two year period. Annual grants to directors generally vest between one and five years following grant. A summary of the option and stock appreciation rights activity for the year ended December 31, 201 7 is as follows:     Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share   Outstanding, December 31, 2016 671,887 $1.45 - $116.40 $8.77  Granted 10,000 $0.62 $0.62  Exercised - - -  Forfeited (268,586) $2.15 - $116.40 $8.06  Outstanding, December 31, 2017 413,301 $0.62 - $54.90 $9.04 As of December 31, 2017, the weighted average remaining contractual life of the options and stock appreciation rights outstanding was 6.07 years. Of the 413,301 options and stock appreciation rights that were outstanding as of December 31, 2017, 339,002 were vested and exercisable with a weighted average exercise price of $10.56 per share and a weighted average remaining term of 5.8 years.  A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows:     Year Ended December 31, 2017  Number of Weighted  Weighted Weighted Options Average Exercise  Options Average Average Currently Price Per Vested  Range of Exercise Prices Outstanding Remaining Life Exercise Price Exercisable Share  $0.00 - $2.00 63,500 7.43 years $ 1.66 38,362 $ 1.86  $2.01 - $4.00 154,001 7.11 years $ 2.15 111,974 $ 2.15  $4.01 - $10.00 126,055 6.24 years $ 4.04 118,921 $ 4.04  $30.01 - $40.00 45,245 2.99 years $ 34.89 45,245 $ 34.89  $40.01 - $50.00 12,250 1.44 years $ 43.90 12,250 $ 43.90  $50.01 - $60.00 12,250 0.41 years $ 54.90 12,250 $ 54.90  413,301 6.07 years $ 9.04 339,002 $ 10.56  The intrinsic value of options and stock appreciation rights is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options and stock appreciation rights that were i n-the-money at December 31, 2017 . The intrinsic value of the options and stock appreciation rights outstanding at December 31, 2017 was approximately $1,800 based on a closing share price of $0.80 on December 31, 2017. There were no fully vested options or stock appreciation rights outstanding at December 31, 2017 with an exercise price less than the closing stock price on December 31, 2017. No options or stock appreciation rights were exercised under the Company’s stock option plans during the years ended December 31, 2016 or 2017 and the Company realized no proceeds during these periods . The weighted average grant date fair value of options and stock appreciation rights granted during the year ended December 31, 2017 was $0.62 per share.  A summary of the restricted stock unit activity for the year ended December 31, 2017 is as follows:   Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit   Outstanding, December 31, 2016 1,167,099 $1.48  Granted 274,736 $0.61  Vested (675,472) $1.51  Forfeited (86,000) $1.43  Outstanding, December 31, 2017 680,363 $1.11 The intrinsic value of restricted stock units outstanding at December 31, 2017 was $0.5 million based on a closing share price of $0.80 as of December 31, 2017 . During the year ended December 31, 201 7 , the aggregate intrinsic value of restric ted stock units vested was $0.4 million determined at the date of vesting. As of December 31, 2017 , the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $0.5 million . This cost will be amortized over a period of up to four years over the underlying estimated service periods and will be adjusted for subsequent changes in actual forfeitures and anticipated vesting periods. 2009 Employee Stock Purchase Plan In 2009, the Company adopted its 2009 Employee Stock Purchase Plan (“ESPP”) . In June 2014, our shareholders approved an amendment of the ESPP to increase the number of shares authorized for issuance under the ESPP by 250,000 shares. Eligible employees have the opportunity to participate in a new purchase period every 3 mo nths . Under the te rms of the plan, employees can purchase up to 15% of their compensation of the Company’s common stock, subject to an annual maximum of $25,000 , at 95% of the fair market value of the stock at the end of the purchase period, subject to certain plan limitations. As of December 31, 201 7 , there were 125,618 remaining shares available for issuance under the Employee Stock Purchase Plan.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Fair Value Measurements [Abstract]
Fair Value Measurements	12. Fair Value Measurements  The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below: Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.  Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.  Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market.  The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.      Fair Value Measurement Using  Total Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  Liabilities at December 31, 2017:  Warrants issued May 2012 $ — $ — $ — $ —  Warrants issued August 2013 5,746 — — 5,746  Warrants issued September 2016 19,569,231 — — 19,569,231  Total liabilities at fair value: $ 19,574,977 $ — $ — $ 19,574,977  Liabilities at December 31, 2016:  Warrants issued May 2012 $ 66,081 $ — $ — $ 66,081  Warrants issued August 2013 151,695 — — 151,695  Warrants issued September 2016 19,569,231 — — 19,569,231  Total liabilities at fair value: $ 19,787,007 $ — $ — $ 19,787,007  Level 1 The Company does not have any financial assets or liabilities classified as Level 1. Level 2 The Company does not have any financial assets or liabilities classified as Level 2. Level 3 In conjunction with the Company’s May 2012, August 2013 and September 2016 financing transactions, the Company issued warrants to purchase shares of the Company’s common stock. Due to the provisions included in the warrant agreements at the time of issuance, the warrants did not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The calculated fair value of the warrants is classified as a liability and is periodically re-measured with any changes in value recognized in “Other income (expense)” in the Statements of Operations. The remaining warrants from the May 2012 transaction (PIPE Warrants) expire in May 2018 and were valued using an option pricing model as of December 31, 2016 using the following assumptions: 1) volatility of 121.12% ; 2) risk-free interest rate of 1.20% ; and 3) a closing stock price of $ 0.65 . The PIPE warrants were revalued using an option pricing model as of December 31, 2017 using the following assumptions: 1) volatility of 68.47% ; 2) risk-free interest rate of 1.76% ; and 3) a closing stock price of $0.80 . The remaining warrants from the August 2013 transaction (Exchange warrants) expire in November 2018 and were valued using an option pricing model as of December 31, 2016 using the follo wing assumptions: 1) volatility of 110.32% ; 2) risk-free interest rate of 1.20% ; and 3) a closing stock price of $ 0.65 . The Exchange warrants were revalued using an option pricing model as of December 31, 2017 using the following assumptions: 1) volatility of 70.56% ; 2) risk-free interest rate of 1.76% ; and 3) a closing stock price of $0.80 . The remaining warrants from the September 2016 warrants expire in September 2021 and were valued using an option pricing model as of December 31, 2016 using the following assumptions: 1) volatility of 121.31% ; 2) risk-free interest rate of 1.93% ; and 3) a closing stock price of $0. 65 . The September 2016 warrants were revalued using an option pricing model as of December 31, 2017 using the following assumptions: 1) volatility of 91.38% ; 2 ) risk-free interest rate of 2.20% ; and 3) a closing stock price of $0.80. The significant unobservable input used in the fair value measurement of the Company’s warrants is volatility. Significant increases (decreases) in the volatility in isolation would result in a significantly higher (lower) liability fair value measurement.  The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the year ended December 31, 201 7 :   Warrants issued May 2012 Warrants issued August 2013 Warrants issued September 2016 Total Liabilities  Balance at beginning of period $ 66,081 $ 151,695 $ 19,569,231 $ 19,787,007  Issues - - - -  Settlements - - - -  Revaluation (66,081) (145,949) - (212,030)  Balance at end of period $ - $ 5,746 $ 19,569,231 $ 19,574,977  The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.  Refer to Note 20 for discussion of subsequent events.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Taxes [Abstract]
Income Taxes	13. Income Taxes  The provision for income taxes consists of the following:   Year Ended December 31,  2017 2016  Deferred:  Federal $ 13,308,196 $ (757,955)  State and local (263,860) (328,867)  13,044,336 (1,086,822)  Valuation allowance (13,044,336) 1,086,822  $ — $ —  The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following:   Year Ended December 31,  2017 2016  U.S. statutory income tax rate 34.0 % 34.0 %  State and local taxes, net of federal tax benefit 1.8 % 1.0 %  Permanent differences between book and tax (1.5) % (15.9) %  Deferred tax adjustments (6.1) % (5.9) %  Tax cuts & jobs act (244.9) % 0.0 %  State rate adjustments (4.0) % 7.4 %  Valuation allowance 220.7 % (20.6) %  Effective income tax rate — % — %   Included in permanent differences between book and tax in the above table are the impacts of the non-deductible mark-to-market activity associated with convertible debt and warrants as well as permanent differences such as nondeductible meals and entertainment and stock compensation shortfalls. The deferred state rate adjustments are a result of changes in apportionment and various state rate law changes. The deferred tax adjustments are primarily attributable to the write-off of deferred tax assets associated with the unexercised stock compensation awards that expired during the current year. The revaluation of the deferred tax assets reflects a $14.5 million provisional write-down as a result of the enactment of the Tax Cuts and Jobs Act on December 22, 2017.  The components of the defe rred tax asset are as follows:   December 31,  2017 2016  Current accruals $ 1,718,808 $ 1,638,298  Deferred revenue 30,648 126,631  Depreciation and amortization 1,311,718 2,131,933  Deferred compensation 633,303 1,464,533  Net operating loss carryovers 22,359,693 33,943,745  Deferred tax assets 26,054,170 39,305,140  Valuation allowance (25,955,759) (39,000,095)  Net deferred tax assets before deferred tax liabilities 98,411 305,045  Accounting method changes (98,411) (305,045)  Net deferred tax assets $ — $ —  On December 22, 2017, the Tax Cuts and Jobs Act ("TCJA") was enacted, which made significant changes to the Internal Revenue Code. The TCJA lowered the U.S. federal income tax rate to 21% , beginning on January 1, 2018. Additionally, among other changes, the TCJA imposes a one-time transition tax on the mandatory repatriation of unremitted foreign earnings, as well as a minimum tax on global intangible low-taxed income ("GILTI") of foreign subsidiaries. Additionally, in response to the enactment of the TCJA, the SEC issued SAB 118 on December 22, 2017. SAB 118 provides for a "measurement period" that allows the Company additional time to complete the accounting for certain tax effects of the TCJA that are considered "provisional" in the Company's financial statements as of December 31, 2017. As of December 31, 2017, the Company had not yet completed its accounting for the TCJA as additional time is needed to evaluate certain factors that could impact the Company's accounting. Such factors include, but are not limited to, the completion of the Company's 2017 income tax returns and changes in interpretations of existing tax laws. However, the Company was able to determine a reasonable estimate of the impacts of the TCJA as of December 31, 2017. As of December 31, 2017, the Company recorded a provisional $14.5 million deferred income tax expense as a result of revaluing the Company's deferred tax assets to incorporate the newly-enacted federal statutory rate of 21%. The $14.5 million deferred tax expense was fully offset as a result of the Company's corresponding release of valuation allowance, resulting in a $14.5 million deferred tax benefit. Additionally, based upon the Company's initial analysis of the one-time transition tax, the Company recorded a provisional amount of $0 associated with the transition tax on mandatory repatriation, as it is estimated that all of the Company's foreign earnings will have been remitted in the U.S. through Subpart F inclusions prior to applying the mandatory repatriation provisions. Additionally, the Company is still in the process of evaluating whether or not to treat the GILTI provisions of the TCJA as a period expense or to provide deferred taxes on certain foreign basis differences. Such policy election will be made within the measurement period as additional guidance and interpretations of existing tax laws become available. Under Section 382 and 383 of the Internal Revenue Code of 1986, as amended, or the “Code”, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. In general, an “ownership change” will occur if there is a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Following significant ownership changes during 2013, the Company initiated a review of the availability of its U.S. net operating loss carryforwards. As a result of this review, it was determined that approximately $288.1 million of the Company’s federal net operating loss carryovers would expire unused due to the limitation under IRC Section 382. The Company reduced the net operating loss carryover and corresponding valuation allowance as a result of these limitations. The remaining net operating loss carryforwards following the ownership change have been assigned a full valuation allowance against all deferred tax assets.  In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable losses, and projections for future periods over which the deferred tax assets are deductible, the Company determined that a 100% valuation allowance of deferred tax assets was appropriate. The valuation allowance for deferred tax assets includes amounts for which subsequently recognized tax benefits will be applied directly to the contributed capital. As of December 31, 2017, we had gross federal net operating loss carryforwards of approximately $98.5 million. The federal net operating loss carryforwards reflect accumulated book losses reduced for the 2013 IRC Section 382 ownership change limitation of $288.1 million and approximately $90 million of book/ tax differences and expiration of unused carryforwards. The federal net operating loss carryforwards will expire between 2030 and 203 7 . As of December 31, 2017, we had state net operating loss deferred tax assets of approximately $1.7 million which will expire at various dates between 2018 and 2037 if not utilized . On February 28, 2018, the Company amended the outstanding warrants issued pursuant to the September 26, 2016 Stock Purchase Agreement providing for a temporary reduction in the exercise price to encourage early exercise. During the restricted exercise period, Stereotaxis received exercise notices for a majorit y of the outstanding warrants. As a result of this tr ansaction, the Company believes that an ownership change may have occurred under Section 382 of the Code . Any change could significantly limit the value of the existing net operating loss carryforward. The Company is currently evaluating the impact of the warrant exercise on the availability of its U.S. net operating loss carryforward . Refer to Note 20 for a full discussion of subsequent events. The Company files income tax returns in the U.S. federal jurisdiction and various state and local jurisdictions. As the Company has a federal n et o perating l oss carryforward from the year ended December 31, 199 8 forward, all tax years from 1998 forward are subject to examination. As states have varying carryforward periods, and the Company has recently entered into additional states, the states are generally subject to examination for the previous 10 years or less. The Company recognizes interest accrued, if any, net of tax and penalties, related to unrecognized tax benefits as components of income tax provision as applicable. As of December 31, 201 7 accrued interest and penalties were less than $0.1 million.  At December 31, 201 7 and 201 6, the Company had approximately $0.1 in reserves for uncertain tax positions.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2017
Net Loss Per Share [Abstract]
Net Loss Per Share	14. Net Loss per Share  The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations:    Twelve months ended December 31,  2017 2016  Net loss $ (5,887,410) $ (5,286,720)  Deemed dividend on convertible preferred stock — (6,145,402)  Cumulative dividend on convertible preferred stock (1,432,259) (368,152)  Net loss attributable to common stockholders $ (7,319,669) $ (11,800,274)   Weighted average number of common shares and equivalents: 22,614,248 21,807,634  Basic EPS $ (0.32) $ (0.54)  Diluted EPS $ (0.32) $ (0.54)  The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows:    December 31,  2017 2016  Shares issuable upon vesting/exercise of:  Options to purchase common stock 413,301 671,887  Series A Convertible Preferred Stock and Accumulated Dividends 39,537,501 37,335,618  Restricted stock units 680,363 1,167,099  Warrants 38,779,119 38,963,443  79,410,284 78,138,047 

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2017
Empoyee Benefit Plan [Abstract]
Employee Benefit Plan	15. Employee Benefit Plan  The Company offers employees the opportunity to participate in a 401(k) plan. E mployer contributions are discretionary under the 401(k) plan. The Company did not match employee contributions made in 2016 or 2017 . 

Product Warranty Provisions

Product Warranty Provisions	12 Months Ended
	Dec. 31, 2017
Product Warranty Provisions [Abstract]
Product Warranty Provisions	16. Product Warranty Provisions  The Company’s standard policy is to warrant all Niobe , Odyssey and Vdrive systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.  Accrued warranty, which is included in other accrued liabilit ies, consists of the following:       December 31, 2017 December 31, 2016  Warranty accrual, beginning of the fiscal period $ 222,845 $ 316,835  Accrual adjustment for product warranty 32,679 103,743  Payments made (91,159) (197,733)  Warranty accrual, end of the fiscal period $ 164,365 $ 222,845 

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	17. Related Party Transactions  In September 2016, the Company entered into a Securities Purchase Agreement with certain institutional and other accredited investors whereby it agreed to sell, for an aggregate purchase price of $24.0 million, (i) an aggregate of 24,000 shares of Series A Convertible Preferred Stock, and (ii) warrants to purchase an aggregate of 36,923,078 shar es of common stock (see Note 11 for further information). Pursuant to the transaction agreements, the Company reimbursed transaction related legal fees of $85,000 to a law firm engaged by DAFNA Capital Management. Funds managed by DAFNA Capital Management own more than 5% of the outstanding shares of the Company. Also, pursuant to the Securities Purchase Agreement, the Board appointed David Fischel, Principal at DAFNA Capital Management, and Joe Kiani, also an investor in the offering, to the Board, effective as of the closing of the Offering. Subsequent to the transaction, the Company reimbursed an additional $120,367 in transaction-related legal fees incurred by law firms engaged by these investors. In February, 2017, David Fischel was appointed acting Chief Executive Officer of Stereotaxis, Inc., and he became Chief Executive Officer during 2017.

Commitments And Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies [Abstract]
Commitments And Contingencies	1 8 . Commitments and Contingencies  The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2017
Segment Information [Abstract]
Segment Information	1 9 . Segment Information  The Company considers reporting segments in accordance with general accounting principles for disclosures about segments of an enterprise and related information. The Company’s system and disposable devices are developed and marketed to a broad base of hospitals in the United States and internationally. The Company considers all such sales to be part of a single operating segment. Geographic revenues for the years ended December 31, 2017 and 2016 were as follows:    Year Ended December 31,  2017 2016  United States $ 18,038,638 $ 19,420,815  International 13,105,462 12,743,301  Total $ 31,144,100 $ 32,164,116 All of the Company’s long-lived assets are located in the United States. Revenues are attributed to countries based on the location of the customer.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	20 . Subsequent Events  On February 28, 2018, the Company entered into a Consent and Amendment with the holders of a majority of the shares of common stock issuable upon exercise of the outstanding warrants (the “SPA Warrants”) issued pursuant to the Stock Purchase Agreement d ated September 26, 2016. The Consent and Amendment amended and restated the SPA Warrants providing for a reduction in the exercise price of the SPA Warrants from $0.70 per share to $0.28 per share for a period between March 1, 2018 and March 5, 2018 to encourage early exercise. Among other changes, the Consent and Amendment also eliminated the right of holders to require the Company to redeem their SPA Warrants in exchange for cash in certain circumstances which required liability accounting for the warrants on the balance sheet. During the restricted exercise period, Stereotaxis received exercise notices for 35,791,927 warrants and received an aggregate of $10.0 million in cash from the warrant exercise. The Consent and Amendment and the Amended and Restated Form of Warrants is available in a Form 8-K filed with the Securities and Exchange Commission on March 6, 2018. 

Valuation And Qualifying Accoun

Valuation And Qualifying Accounts	12 Months Ended
	Dec. 31, 2017
Valuation And Qualifying Accounts [Abstract]
Valuation And Qualifying Accounts	SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS FOR THE YEARS ENDED DECEMBER 31, 201 7 A ND 2016    Additions  Balance at Charged to  Beginning of Cost and Balance at the  Year Expenses Deductions End of Year  Allowance for doubtful accounts and returns:  Year ended December 31, 2017 $ 379,817 $ (18,467) $ 0 $ 361,350  Year ended December 31, 2016 $ 93,478 $ 292,690 $ (6,351) $ 379,817   Allowance for inventories valuation:  Year ended December 31, 2017 $ 272,614 $ 3,948,726 $ (319,568) $ 3,901,772  Year ended December 31, 2016 $ 19,971 $ 283,441 $ (30,798) $ 272,614 

Summary Of Significant Accoun29

Summary Of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Basis Of Presentation	Basis of Presentation The Company believes the cash on hand at December 31, 2017 plus the $10 million of proceeds from the March 2018 financing will be sufficient to meet its obligations as they become due in the ordinary course of business for at least 12 months following the date these financial statements are issued. The Company has sustained operating losses throughout its corporate history and expects that its 2018 expenses will exceed its 2018 gross margin. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations or expense reductions are in place. The Company’s liquidity needs will be largely determined by the success of clinical adoption within the installed base of Niobe systems as well as by new placements of capital systems. The Company also may consider raising cash through capital transactions, which could include either debt or equity financing.
Cash And Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. No cash was restricted at December 31, 2017 or 2016.
Accounts Receivable And Allowance For Uncollectible Accounts	Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators.
Financial Instruments	Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 12 for disclosure of fair value measurements. 
Inventory	Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items.
Property And Equipment	Property and Equipment Property and equipment consist primarily of leasehold improvements, computer, office, research and demonstration equipment, and equipment held for lease and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years.
Long-Lived Assets	Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs .
Intangible Assets	Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10 - 15 years. If facts and circumstances suggest that an intangible asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs .
Use Of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates.
Revenue And Costs Of Revenue	Revenue and Costs of Revenue The Company recognizes revenue based on the Multiple-Deliverable Revenue Arrangements guidance (“ASU 2009-13”). ASU 2009-13 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimis effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Research And Development Costs	Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts rec eivable from strategic relationships under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables at December 31, 2017 or 2016 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned.
Share-Based Compensation	Share-Based Compensation Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is remeasured on a quarterly basis through the vesting or forfeiture date. The Company utilized the Black-Scholes valuation model to determine the fair value of share-based payments at the date of previously issued grant using risk-free interest rate based on the Treasury yield on the date of the grant and expected volatility based on the Company’s historical volatility over the expected term of the option. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Restricted shares and units granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments. Shares purchased by employees under the 2009 Employee Stock Purchase Plan are considered to be non-compensatory.
Net Earnings (Loss) per Common Share	Net Earnings (Loss) per Common Share Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our Convertible Preferred Stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our Convertible Preferred Stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, warrants, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our Convertible Preferred Stock issued and outstanding during the period, except where the effect of such securities would be antidilutive . The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights, warrants or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. As of December 31, 2017, the Company had 413,301 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $9.04 per share, 38,779,119 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $0.82 per share, and 39,537,501 shares of our common stock issuable upon conversion of our Series A Convertible Preferred Stock. The Company had no unearned restricted shares outstanding for the period ended December 31, 2017.
Income Taxes	Income Taxes In accordance with general accounting principles for income taxes , a deferred income tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized.
Product Warranty Provisions	Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate.
Patent Costs	Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.
Concentrations Of Risk	Concentrations of Risk The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of government provided insurance on such deposits. Revenue from Biosense Webster Inc. related to royalties and Odyssey system sales accounted for $3,304,126 and $4,099,075 or 11% , and 13% , of total net revenue for the years ended December 31, 2017, and 2016, respectively. No other single customer accounted for more than 10% of total revenue for the year ended December 31, 2017.
Reclassifications	Reclassifications Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements  In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” This amendment is intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, forfeitures, and classification on the statement of cash flows. This update was effective for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company) and interim periods within those fiscal years, with earlier application permitted. The Company adopted this guidance in the first quarter of 2017. The adoption of ASU 2016-09 did not materially impact the Company’s consolidated financial position, results of operations, equity, or cash flows.  In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” regarding the subsequent measurement of inventory as part of its Simplification Initiative. This standard was effective for public companies for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company), including interim periods within those fiscal years. This Update should be applied prospectively, and early application is permitted as of the beginning of an interim or annual reporting period. The Company adopted this accounting standard update in the first quarter of 2017. The adoption of ASU 2015-11 did not materially impact the company’s results of operations, financial conditions, cash flows, or financial statement presentation.  In November 2015, the FASB issued Accounting Standards Update (“ASU” or “Update”) No. 2015-17, “Income Taxes (Topic 740): To simplify the presentation of deferred income taxes.” The amendments in this Update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. This standard is effective for public companies for financial statements issued for annual periods beginning after December 15, 2016 (January 1, 2017 for the Company), and interim periods within those annual periods. We have adopted this accounting standard update and there was no impact to the results of operations or cash flows  In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02 - Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update.  In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists or when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter of 2017 (December 31, 2016 for the Company). We have adopted this accounting standard update and provided the relevant disclosures in Note 1. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers," which converges the FASB's and the International Accounting Standards Board's current standards on revenue recognition. The standard provides companies with a single model to use in accounting for revenue arising from contracts with customers and supersedes current revenue guidance. The core principle of the ASU is that an entity should recognize revenue for the transfer of goods or services equal to the amount that it expects to be entitled to receive for those goods or services. ASU 2014-09 requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments. The standard is effective for annual and interim periods beginning after December 15, 2017 (January 1, 2018 for the Company). Early adoption is not permitted. The standard permits companies to either apply the adoption to all periods presented, or apply the requirements in the year of adoption through a cumulative adjustment. The Company will adopt ASU 2014-09 during the first quarter of 2018 using the modified retrospective method. We are substantially complete with our evaluation of the impact of adopting ASU 2014-09 on our consolidated financial statements, and we do not expect significant changes in the timing or method of revenue recognition for any of our material revenue streams. In connection with adopting ASU 2014-09, we expect to record a cumulative-effect reduction to accumulated deficit of $0.4 million on January 1, 2018. This adjustment primarily relates to the deferral of costs to obtain a contract that were previously expensed at the beginning of the contract period .

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory [Abstract]
Schedule Of Inventories	  December 31, 2017 December 31, 2016   Raw materials $ 2,528,270 $ 2,397,430  Work in process 4,836 341,125  Finished goods 2,515,637 2,915,162  Reserve for obsolescence (3,901,772) (272,614)  Total inventory $ 1,146,971 $ 5,381,103 

Prepaid Expenses And Other Cu31

Prepaid Expenses And Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Prepaid Expenses And Other Current Assets [Abstract]
Schedule Of Prepaid Expenses And Other Current Assets	   December 31, 2017 December 31, 2016   Prepaid expenses $ 575,501 $ 575,886  Deferred financing costs 24,658 24,658  Deposits 194,358 293,992  Total prepaid expenses and other assets 794,517 894,536  Less: Noncurrent prepaid expenses and other assets (44,432) (39,241)  Total current prepaid expenses and other assets $ 750,085 $ 855,295 

Property And Equipment (Tables)

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property And Equipment [Abstract]
Schedule Of Property And Equipment	  December 31, December 31,  2017 2016   Equipment $ 7,295,698 $ 8,397,528  Equipment held for lease - 303,412  Leasehold improvements 2,592,339 2,719,860  9,888,037 11,420,800  Less: Accumulated depreciation (9,295,349) (10,334,556)  Net property and equipment $ 592,688 $ 1,086,244 

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Accrued Liabilities [Abstract]
Schedule Of Accrued Liabilities	  December 31, December 31,  2017 2016   Accrued salaries, bonus, and benefits $ 1,641,491 $ 2,452,183  Accrued rent 441,417 965,412  Accrued licenses and maintenance fees 581,672 561,450  Accrued warranties 164,365 222,845  Accrued taxes 234,668 219,017  Accrued professional services 367,072 180,450  Other 299,931 210,216  Total accrued liabilities 3,730,616 4,811,573  Less: Long term accrued liabilities (535,369) (320,409)  Total current accrued liabilities $ 3,195,247 $ 4,491,164 

Deferred Revenue (Tables)

Deferred Revenue (Tables)	12 Months Ended
	Dec. 31, 2017
Deferred Revenue [Abstract]
Schedule Of Deferred Revenue	  December 31, December 31,  2017 2016   Product shipped, revenue deferred $ 941,724 $ 549,709  Customer deposits - 2,910,000  Deferred service and license fees 5,372,908 5,813,956  Total deferred revenue 6,314,632 9,273,665  Less: Long-term deferred revenue (611,863) (522,329)  Total current deferred revenue $ 5,702,769 $ 8,751,336 

Lease Obligations (Tables)

Lease Obligations (Tables)	12 Months Ended
	Dec. 31, 2017
Lease Obligations [Abstract]
Schedule Of Future Minimum Lease Payments	   Year Operating Lease Payments  2018 $ 2,067,392  2019 11,497  2020 8,622  Total minimum lease payments 2,087,511  Less amounts representing sublease receipts (764,917)  $ 1,322,594 

Convertible Preferred Stock A36

Convertible Preferred Stock And Stockholder's Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Convertible Preferred Stock And Stockholders' Equity [Abstract]
Summary Of Reserved Shares Of Common Stock	  December 31, December 31,  2017 2016  Warrants 38,779,119 38,963,443  Series A Convertible Preferred Stock Series 47,844,562 47,844,562  Stock award plans 5,573,046 1,524,996  Employee Stock Purchase Plan 125,618 192,290  92,322,345 88,525,291 
Summary Of Option And Stock Appreciation Rights Activity	  Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share   Outstanding, December 31, 2016 671,887 $1.45 - $116.40 $8.77  Granted 10,000 $0.62 $0.62  Exercised - - -  Forfeited (268,586) $2.15 - $116.40 $8.06  Outstanding, December 31, 2017 413,301 $0.62 - $54.90 $9.04 
Summary Of Options And Stock Appreciation Rights Outstanding By Range Of Exercise Price	  Year Ended December 31, 2017  Number of Weighted  Weighted Weighted Options Average Exercise  Options Average Average Currently Price Per Vested  Range of Exercise Prices Outstanding Remaining Life Exercise Price Exercisable Share  $0.00 - $2.00 63,500 7.43 years $ 1.66 38,362 $ 1.86  $2.01 - $4.00 154,001 7.11 years $ 2.15 111,974 $ 2.15  $4.01 - $10.00 126,055 6.24 years $ 4.04 118,921 $ 4.04  $30.01 - $40.00 45,245 2.99 years $ 34.89 45,245 $ 34.89  $40.01 - $50.00 12,250 1.44 years $ 43.90 12,250 $ 43.90  $50.01 - $60.00 12,250 0.41 years $ 54.90 12,250 $ 54.90  413,301 6.07 years $ 9.04 339,002 $ 10.56 
Summary Of Restricted Stock Unit Activity	  Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit   Outstanding, December 31, 2016 1,167,099 $1.48  Granted 274,736 $0.61  Vested (675,472) $1.51  Forfeited (86,000) $1.43  Outstanding, December 31, 2017 680,363 $1.11 

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Measurements [Abstract]
Assets And Liabilities Measured At Fair Value On Recurring Basis By Level	  Fair Value Measurement Using  Total Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  Liabilities at December 31, 2017:  Warrants issued May 2012 $ — $ — $ — $ —  Warrants issued August 2013 5,746 — — 5,746  Warrants issued September 2016 19,569,231 — — 19,569,231  Total liabilities at fair value: $ 19,574,977 $ — $ — $ 19,574,977  Liabilities at December 31, 2016:  Warrants issued May 2012 $ 66,081 $ — $ — $ 66,081  Warrants issued August 2013 151,695 — — 151,695  Warrants issued September 2016 19,569,231 — — 19,569,231  Total liabilities at fair value: $ 19,787,007 $ — $ — $ 19,787,007 
Summary Of Changes In Fair Value Of Level 3 Financial Liabilities	  Warrants issued May 2012 Warrants issued August 2013 Warrants issued September 2016 Total Liabilities  Balance at beginning of period $ 66,081 $ 151,695 $ 19,569,231 $ 19,787,007  Issues - - - -  Settlements - - - -  Revaluation (66,081) (145,949) - (212,030)  Balance at end of period $ - $ 5,746 $ 19,569,231 $ 19,574,977 

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Taxes [Abstract]
Schedule Of Provision For Income Taxes	  Year Ended December 31,  2017 2016  Deferred:  Federal $ 13,308,196 $ (757,955)  State and local (263,860) (328,867)  13,044,336 (1,086,822)  Valuation allowance (13,044,336) 1,086,822  $ — $ — 
Schedule Of Reconciliation Of Federal Income Tax Rate	  Year Ended December 31,  2017 2016  U.S. statutory income tax rate 34.0 % 34.0 %  State and local taxes, net of federal tax benefit 1.8 % 1.0 %  Permanent differences between book and tax (1.5) % (15.9) %  Deferred tax adjustments (6.1) % (5.9) %  Tax cuts & jobs act (244.9) % 0.0 %  State rate adjustments (4.0) % 7.4 %  Valuation allowance 220.7 % (20.6) %  Effective income tax rate — % — % 
Schedule Of Components Of Deferred Tax Asset	  December 31,  2017 2016  Current accruals $ 1,718,808 $ 1,638,298  Deferred revenue 30,648 126,631  Depreciation and amortization 1,311,718 2,131,933  Deferred compensation 633,303 1,464,533  Net operating loss carryovers 22,359,693 33,943,745  Deferred tax assets 26,054,170 39,305,140  Valuation allowance (25,955,759) (39,000,095)  Net deferred tax assets before deferred tax liabilities 98,411 305,045  Accounting method changes (98,411) (305,045)  Net deferred tax assets $ — $ — 

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Net Loss Per Share [Abstract]
Schedule Of Computation Of Basic And Diluted Earnings Per Share	  Twelve months ended December 31,  2017 2016  Net loss $ (5,887,410) $ (5,286,720)  Deemed dividend on convertible preferred stock — (6,145,402)  Cumulative dividend on convertible preferred stock (1,432,259) (368,152)  Net loss attributable to common stockholders $ (7,319,669) $ (11,800,274)   Weighted average number of common shares and equivalents: 22,614,248 21,807,634  Basic EPS $ (0.32) $ (0.54)  Diluted EPS $ (0.32) $ (0.54) 
Schedule Of Anti-Dilutive Securities Excluded From Computation Of Diluted Earnings Per Share	  December 31,  2017 2016  Shares issuable upon vesting/exercise of:  Options to purchase common stock 413,301 671,887  Series A Convertible Preferred Stock and Accumulated Dividends 39,537,501 37,335,618  Restricted stock units 680,363 1,167,099  Warrants 38,779,119 38,963,443  79,410,284 78,138,047 

Product Warranty Provisions (Ta

Product Warranty Provisions (Tables)	12 Months Ended
	Dec. 31, 2017
Product Warranty Provisions [Abstract]
Schedule Of Accrued Warranty	  December 31, 2017 December 31, 2016  Warranty accrual, beginning of the fiscal period $ 222,845 $ 316,835  Accrual adjustment for product warranty 32,679 103,743  Payments made (91,159) (197,733)  Warranty accrual, end of the fiscal period $ 164,365 $ 222,845 

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Information [Abstract]
Schedule Of Geographic Revenues	  Year Ended December 31,  2017 2016  United States $ 18,038,638 $ 19,420,815  International 13,105,462 12,743,301  Total $ 31,144,100 $ 32,164,116 

Description Of Business (Detail

Description Of Business (Details) $ in Millions	Mar. 05, 2018USD ($)	Dec. 31, 2017item
Installed base | item		128
Subsequent Event [Member]
Proceeds from Warrant Exercises | $	$ 10

Summary Of Significant Accoun43

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Jan. 01, 2018	Sep. 29, 2016	Sep. 26, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted cash	$ 0	$ 0
Research and development receivables	$ 0	$ 0
Exercise price of warrants				$ 0.70	$ 0.70
Reserved shares of common stock	92,322,345	88,525,291
Revenues	$ 31,144,100	$ 32,164,116
Accounting Standards Update 2014-09 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effect on accumulated deficit			$ 400,000
Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved shares of common stock	39,537,501
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Property and equipment, estimated useful lives	3 years
Intangible assets, estimated useful lives	10 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Property and equipment, estimated useful lives	10 years
Intangible assets, estimated useful lives	15 years
Deferred Service And License Fees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred revenue, amortization period	1 year
Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options and stock appreciation rights outstanding	413,301	671,887
Weighted average exercise price	$ 9.04	$ 8.77
Stock Options And Stock Appreciation Rights [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, requisite service period	1 year
Stock Options And Stock Appreciation Rights [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, requisite service period	4 years
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issuable upon exercise	38,779,119
Exercise price of warrants	$ 0.82
Reserved shares of common stock	38,779,119	38,963,443
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested restricted shares	680,363	1,167,099
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested restricted shares	0
Biosense Webster Inc [Member] | Net Revenue [Member] | Customer Concentration Risk [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Revenues	$ 3,304,126	$ 4,099,075
Revenues percentage	11.00%	13.00%

Inventory (Details)

Inventory (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Inventory [Abstract]
Raw materials	$ 2,528,270	$ 2,397,430
Work in process	4,836	341,125
Finished goods	2,515,637	2,915,162
Reserve for obsolescence	(3,901,772)	(272,614)
Total inventory	$ 1,146,971	$ 5,381,103

Prepaid Expenses And Other Cu45

Prepaid Expenses And Other Current Assets (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid expenses	$ 575,501	$ 575,886
Deferred financing costs	24,658	24,658
Deposits	194,358	293,992
Total prepaid expenses and other assets	794,517	894,536
Less: Noncurrent prepaid expenses and other assets	(44,432)	(39,241)
Total current prepaid expenses and other assets	$ 750,085	$ 855,295

Property And Equipment (Details

Property And Equipment (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 9,888,037	$ 11,420,800
Less: Accumulated depreciation	(9,295,349)	(10,334,556)
Net property and equipment	592,688	1,086,244
Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	7,295,698	8,397,528
Equipment Held For Lease [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment		303,412
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 2,592,339	$ 2,719,860

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Intangible Assets [Abstract]
Total intangible assets	$ 3,143,291	$ 3,221,069
Accumulated amortization	2,983,821	2,784,500
Amortization expense	199,321	$ 199,320
Future amortization expense in 2018	65,988
Future amortization expense in 2019	65,988
Future amortization expense in 2020	27,495
Impairment charges	$ 77,778

Accrued Liabilities (Schedule O

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accrued Liabilities [Abstract]
Accrued salaries, bonus, and benefits	$ 1,641,491	$ 2,452,183
Accrued rent	441,417	965,412
Accrued licenses and maintenance fees	581,672	561,450
Accrued warranties	164,365	222,845	$ 316,835
Accrued taxes	234,668	219,017
Accrued professional services	367,072	180,450
Other	299,931	210,216
Total accrued liabilities	3,730,616	4,811,573
Less: Long term accrued liabilities	(535,369)	(320,409)
Total current accrued liabilities	$ 3,195,247	$ 4,491,164

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 6,314,632	$ 9,273,665
Less: Long-term deferred revenue	(611,863)	(522,329)
Total current deferred revenue	5,702,769	8,751,336
Product Shipped, Revenue Deferred [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	941,724	549,709
Customer Deposits [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue		2,910,000
Deferred Service And License Fees [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 5,372,908	$ 5,813,956

Long-Term Debt And Credit Fac50

Long-Term Debt And Credit Facilities (Narrative) (Details) - USD ($)	Jan. 31, 2013	Aug. 08, 2012	Nov. 30, 2011	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Principal amount of long term debt					$ 0	$ 0
Total liquidity					6,400,000
Cash and cash equivalents					3,686,302	8,501,392	$ 5,593,582
Payments of debt						13,020,780
Gain on debt extinguishment						5,632,171
Healthcare Royalty Partners Debt [Member]
Debt Instrument [Line Items]
Amount of debt extinguished				$ 18,100,000
Deferred financing costs				300,000
Accrued interest				500,000
Payments of debt				$ 13,000,000	$ 13,000,000
Term Loan [Member] | Healthcare Royalty Partners Debt [Member]
Debt Instrument [Line Items]
Amount borrowed	$ 2,500,000	$ 2,500,000	$ 15,000,000
Additional amount which may be borrowed			$ 5,000,000
Percentage of royalties entitled to receive			100.00%
Maturity date					Dec. 31, 2018
Annual interest rate			16.00%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity					$ 5,000,000	$ 10,000,000
Line of credit facility, maturity date					Mar. 31, 2018
Minimum tangible net worth requirement, period one					$ (24,000,000)
Minimum tangible net worth requirement, period two					(24,500,000)
Line of credit facility, amount outstanding					0
Line of credit facility, current borrowing capacity					$ 2,700,000
Annual interest rate					5.75%	7.00%
Minimum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Liquidity ratio					1.50

Lease Obligations (Narrative) (

Lease Obligations (Narrative) (Details)	12 Months Ended
	Dec. 31, 2017USD ($)ft²	Dec. 31, 2016USD ($)ft²	Dec. 31, 2015ft²	Sep. 30, 2013USD ($)ft²
Property Subject to or Available for Operating Lease [Line Items]
Rent expense	$ 588,197	$ 1,187,989
Sublease income	$ 812,660	91,579
Lease renewal term	3 years
Accrued costs of rent liability	$ 441,417	$ 965,412
Unimproved [Member]
Property Subject to or Available for Operating Lease [Line Items]
Square feet of leased space | ft²				13,000
Accrued lease termination costs remaining	$ 95,455
Accrued costs of rent liability				$ 515,138
Office [Member]
Property Subject to or Available for Operating Lease [Line Items]
Square feet of leased space | ft²			3,152
Office Sublease [Member]
Property Subject to or Available for Operating Lease [Line Items]
Square feet of leased space | ft²		11,000
Office Sublease, January 2017 [Member]
Property Subject to or Available for Operating Lease [Line Items]
Square feet of leased space | ft²	16,000
Accrued lease termination costs remaining	$ 26,202
Sublease expiration date	Dec. 31, 2018

Lease Obligations (Schedule of

Lease Obligations (Schedule of Future Minimum Lease Payments) (Details)	Dec. 31, 2017USD ($)
Lease Obligations [Abstract]
2,018	$ 2,067,392
2,019	11,497
2,020	8,622
Total minimum lease payments	2,087,511
Less amounts representing sublease receipts	(764,917)
Net minimum lease payments	$ 1,322,594

Convertible Preferred Stock A53

Convertible Preferred Stock And Stockholders' Equity (Narrative) (Details)	Mar. 05, 2018$ / sharesshares	Sep. 29, 2016USD ($)$ / sharesshares	Sep. 30, 2016USD ($)	Jun. 30, 2014shares	May 31, 2014USD ($)	Dec. 31, 2017USD ($)$ / sharesitemshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2009USD ($)	Sep. 26, 2016$ / shares
Shareholders' Equity and Share-based Payments [Line Items]
Votes per share | item						1
Dividends declared						$ 0
Dividends paid						$ 0
Proceeds from preferred stock and warrants issued, gross		$ 24,000,000
Preferred stock, shares issued | shares		24,000
Preferred stock, par value | $ / shares						$ 0.001	$ 0.001
Preferred Stock, Liquidation Preference, Value						$ 1,000
Common stock issuable from warrants | shares		36,923,078
Proceeds from preferred stocks and warrants, net		$ 23,000,000
Payments of debt							$ 13,020,780
Preferred stock dividend rate						6.00%
Preferred stock, conversion price | $ / shares						$ 0.65
Preferred stock redemption, triggering event, Percent of common stock sold threshold						50.00%
Preferred stock, Accretion of dicount						$ 6,100,000	6,145,402
Exercise price of warrants | $ / shares		$ 0.70							$ 0.70
Proceeds from issuance of stock, net of issuance costs						41,054	$ 23,001,528
Total compensation cost not yet recognized						$ 500,000
Weighted average amortization period of total compensation cost not yet recognized						4 years
Subsequent Event [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Exercise price of warrants | $ / shares	$ 0.28
Number of warrants exercised | shares	35,791,927
Convertible Preferred Stock [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Shares converted | shares							100
Common Stock [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Shares issued in conversion | shares							155,439
2009 Employee Stock Purchase Plan [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Exercise price as percentage of fair value								95.00%
Increase in number of shares authorized for issuance under the Plan | shares				250,000
Eligible employees new purchase period						3 months
Maximum percentage of compensation eligible employees can use to purchase common stock								15.00%
Compensation amount eligible employees can use to purchase common stock, maximum								$ 25,000
Remaining shares available for issuance | shares						125,618
Sales Agreement [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Aggregate gross sales price					$ 18,000,000
Commission percentage of gross proceeds					3.00%
Stock Options And Stock Appreciation Rights [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options expiration term						10 years
Options and stock appreciation rights outstanding | shares						413,301	671,887
Options and stock appreciation rights vested and exercisable | shares						339,002
Weighted average remaining contractual life						6 years 26 days
Options vested with exercise price below share price | shares						0
Options and stock appreciation rights exercised | shares						0	0
Options and stock appreciation rights weighted average exercise price | $ / shares						$ 10.56
Options and stock appreciation rights weighted average remaining term						5 years 9 months 18 days
Options and stock appreciation rights intrinsic value						$ 1,800
Proceeds from options and stock appreciation rights exercised						$ 0	$ 0
Weighted average grant date fair value of options and stock appreciation rights granted | $ / shares						$ 0.62
Share price | $ / shares						$ 0.80
Stock Options And Stock Appreciation Rights [Member] | Tranche One [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting percentage						25.00%
Stock Options And Stock Appreciation Rights [Member] | Tranche Two [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting percentage						2.0833%
Options vesting period						3 years
Stock Options And Stock Appreciation Rights [Member] | Director [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options expiration term						10 years
Stock Options And Stock Appreciation Rights [Member] | Director [Member] | Tranche One [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting period						2 years
Stock Options And Stock Appreciation Rights [Member] | Minimum [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Exercise price as percentage of fair value						100.00%
Stock Options And Stock Appreciation Rights [Member] | Minimum [Member] | Director [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Exercise price as percentage of fair value						100.00%
Warrants [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Exercise price of warrants | $ / shares						$ 0.82
Stock Appreciation Rights [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options expiration term						10 years
Stock Appreciation Rights [Member] | Tranche One [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting percentage						25.00%
Stock Appreciation Rights [Member] | Tranche Two [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting percentage						2.0833%
Options vesting period						3 years
Restricted Stock [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting period						3 years
Restricted shares outstanding | shares						0
Restricted Stock Units [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting period						4 years
Intrinsic value of restricted awards outstanding						$ 500,000
Intrinsic value of restricted awards vested						$ 400,000
Restricted shares outstanding | shares						680,363	1,167,099
Share price | $ / shares						$ 0.80
Healthcare Royalty Partners Debt [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Payments of debt			$ 13,000,000			$ 13,000,000

Convertible Preferred Stock A54

Convertible Preferred Stock And Stockholders' Equity (Summary Of Reserved Shares Of Common Stock) (Details) - shares	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved shares of common stock	92,322,345	88,525,291
Series A Convertible Preferred Stock Series [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved shares of common stock	47,844,562	47,844,562
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved shares of common stock	38,779,119	38,963,443
Stock Award Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved shares of common stock	5,573,046	1,524,996
2009 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved shares of common stock	125,618	192,290

Convertible Preferred Stock A55

Convertible Preferred Stock And Stockholders' Equity (Summary Of Option And Stock Appreciation Rights Activity) (Details) - Stock Options And Stock Appreciation Rights [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Outstanding, December 31, 2016	671,887
Number of Options/SARs, Granted	10,000
Number of Options/SARs, Exercised	0	0
Number of Options/SARs, Forfeited	(268,586)
Number of Options/SARs, Outstanding, December 31, 2017	413,301	671,887
Weighted Average Exercise Price per Share, Outstanding, December 31, 2016	$ 8.77
Weighted Average Exercise Price per Share, Granted	0.62
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, Forfeited	8.06
Weighted Average Exercise Price per Share, Outstanding, December 31, 2017	9.04	$ 8.77
$1.45 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit		1.45
Range of Exercise Price, Upper Limit		$ 116.40
$0.62 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted Average Exercise Price per Share, Granted	0.62
$2.15 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	0.62
Range of Exercise Price, Upper Limit	54.90
$0.62 - $54.90 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	2.15
Range of Exercise Price, Upper Limit	$ 116.40

Convertible Preferred Stock A56

Convertible Preferred Stock And Stockholders' Equity (Summary Of Options And Stock Appreciation Rights Outstanding By Range Of Exercise Price) (Details) - Stock Options And Stock Appreciation Rights [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding	413,301	671,887
Weighted Average Remaining Life	6 years 26 days
Weighted Average Exercise Price	$ 9.04	$ 8.77
Number of Options Currently Exercisable	339,002
Weighted Average Exercise Price per Vested Share	$ 10.56
$0.00 - $2.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	0
Range of Exercise Price, Upper Limit	$ 2
Options Outstanding	63,500
Weighted Average Remaining Life	7 years 5 months 5 days
Weighted Average Exercise Price	$ 1.66
Number of Options Currently Exercisable	38,362
Weighted Average Exercise Price per Vested Share	$ 1.86
$2.01 - $4.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	2.01
Range of Exercise Price, Upper Limit	$ 4
Options Outstanding	154,001
Weighted Average Remaining Life	7 years 1 month 10 days
Weighted Average Exercise Price	$ 2.15
Number of Options Currently Exercisable	111,974
Weighted Average Exercise Price per Vested Share	$ 2.15
$4.01 - $10.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	4.01
Range of Exercise Price, Upper Limit	$ 10
Options Outstanding	126,055
Weighted Average Remaining Life	6 years 2 months 27 days
Weighted Average Exercise Price	$ 4.04
Number of Options Currently Exercisable	118,921
Weighted Average Exercise Price per Vested Share	$ 4.04
$30.01 - $40.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	30.01
Range of Exercise Price, Upper Limit	$ 40
Options Outstanding	45,245
Weighted Average Remaining Life	2 years 11 months 27 days
Weighted Average Exercise Price	$ 34.89
Number of Options Currently Exercisable	45,245
Weighted Average Exercise Price per Vested Share	$ 34.89
$40.01 - $50.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	40.01
Range of Exercise Price, Upper Limit	$ 50
Options Outstanding	12,250
Weighted Average Remaining Life	1 year 5 months 9 days
Weighted Average Exercise Price	$ 43.90
Number of Options Currently Exercisable	12,250
Weighted Average Exercise Price per Vested Share	$ 43.90
$50.01 - $60.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	50.01
Range of Exercise Price, Upper Limit	$ 60
Options Outstanding	12,250
Weighted Average Remaining Life	4 months 28 days
Weighted Average Exercise Price	$ 54.90
Number of Options Currently Exercisable	12,250
Weighted Average Exercise Price per Vested Share	$ 54.90

Convertible Preferred Stock A57

Convertible Preferred Stock And Stockholders' Equity (Summary Of Restricted Stock Unit Activity) (Details) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Stock Units, Outstanding, December 31, 2016 | shares	1,167,099
Number of Restricted Stock Units, Granted | shares	274,736
Number of Restricted Stock Units, Vested | shares	(675,472)
Number of Restricted Stock Units, Forfeited | shares	(86,000)
Number of Restricted Stock Units, Outstanding, December 31, 2017 | shares	680,363
Weighted Average Grant Date Fair Value per Unit, Outstanding, December 31, 2016 | $ / shares	$ 1.48
Weighted Average Grant Date Fair Value per Unit, Granted | $ / shares	0.61
Weighted Average Grant Date Fair Value per Unit, Vested | $ / shares	1.51
Weighted Average Grant Date Fair Value per Unit, Forfeited | $ / shares	1.43
Weighted Average Grant Date Fair Value per Unit, Outstanding, December 31, 2017 | $ / shares	$ 1.11

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Volatility rate	121.31%	91.38%
Risk-free interest rate	1.93%	2.20%
Closing stock price	$ 0.65	$ 0.80
Significant Unobservable Inputs (Level 3) [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant expiration date		May 1, 2018
Volatility rate		68.47%	121.12%
Risk-free interest rate		1.76%	1.20%
Closing stock price		$ 0.80	$ 0.65
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant expiration date		Nov. 1, 2018
Volatility rate		70.56%	110.32%
Risk-free interest rate		1.76%	1.20%
Closing stock price		$ 0.80	$ 0.65

Fair Value Measurements (Assets

Fair Value Measurements (Assets And Liabilities Measured At Fair Value On Recurring Basis By Level) (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	$ 19,574,977	$ 19,787,007
Total liabilities at fair value	19,574,977	19,787,007
Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued		66,081
Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	5,746	151,695
Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	19,569,231	19,569,231
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member] | Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	19,574,977	19,787,007
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued		66,081
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	5,746	151,695
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	$ 19,569,231	$ 19,569,231

Fair Value Measurements (Summar

Fair Value Measurements (Summary Of Changes In Fair Value Of Level 3 Financial Liabilities) (Details)	12 Months Ended
	Dec. 31, 2017USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	$ 19,787,007
Issues
Settlements
Revaluation	(212,030)
Balance at end of period	19,574,977
Warrants Issued May 2012 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	66,081
Issues
Settlements
Revaluation	(66,081)
Warrants Issued August 2013 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	151,695
Issues
Settlements
Revaluation	(145,949)
Balance at end of period	5,746
Warrants Issued September 2016 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	19,569,231
Issues
Settlements
Balance at end of period	$ 19,569,231

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating Loss Carryforwards [Line Items]
U.S. statutory income tax rate		34.00%	34.00%
Change in tax rate, deferred tax asset valuation		$ 14,500,000
Change in tax rate, transition tax		$ 0
Valid portion of valuation allowance percentage		100.00%
Permanent book/tax differences and expirations		$ 90,000,000
Accrued interest and penalties		100,000
Reserves for uncertain tax positions		100,000	$ 100,000
Scenario, Plan [Member]
Operating Loss Carryforwards [Line Items]
U.S. statutory income tax rate	21.00%
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryovers expiring unused		288,100,000
Operating loss carryforwards		$ 98,500,000
Federal [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date		Dec. 31, 2030
Federal [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date		Dec. 31, 2037
Federal [Member] | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Tax year subject to examination		1,998
State [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		$ 1,700,000
Number of prior years subject to examination		10 years
State [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date		Dec. 31, 2018
State [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date		Dec. 31, 2037

Income Taxes (Schedule Of Provi

Income Taxes (Schedule Of Provision For Income Taxes) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Abstract]
Federal	$ 13,308,196	$ (757,955)
State and local	(263,860)	(328,867)
Total deferred income tax expense (benefit)	13,044,336	(1,086,822)
Valuation allowance	(13,044,336)	1,086,822
Income tax benefit

Income Taxes (Schedule Of Recon

Income Taxes (Schedule Of Reconciliation Of Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax [Line Items]
U.S. statutory income tax rate	34.00%	34.00%
State and local taxes, net of federal tax benefit	1.80%	1.00%
Permanent differences between book and tax	(1.50%)	(15.90%)
Deferred tax adjustments	(6.10%)	(5.90%)
Valuation allowance	220.70%	(20.60%)
Effective income tax rate
Federal [Member]
Income Tax [Line Items]
Rate adjustments	(244.90%)	0.00%
State [Member]
Income Tax [Line Items]
Rate adjustments	(4.00%)	7.40%

Income Taxes (Schedule Of Compo

Income Taxes (Schedule Of Components Of Deferred Tax Asset) (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Abstract]
Current accruals	$ 1,718,808	$ 1,638,298
Deferred revenue	30,648	126,631
Depreciation and amortization	1,311,718	2,131,933
Deferred compensation	633,303	1,464,533
Net operating loss carryovers	22,359,693	33,943,745
Deferred tax assets	26,054,170	39,305,140
Valuation allowance	(25,955,759)	(39,000,095)
Net deferred tax assets before deferred tax liabilities	98,411	305,045
Accounting method changes	(98,411)	(305,045)
Net deferred tax assets

Net Loss Per Share (Schedule Of

Net Loss Per Share (Schedule Of Computation Of Basic And Diluted Earnings Per Share) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Net Loss Per Share [Abstract]
Net loss	$ (5,887,410)	$ (5,286,720)
Deemed dividend on convertible preferred stock		(6,145,402)
Cumulative dividend on convertible preferred stock	(1,432,259)	(368,152)
Net loss attributable to common stockholders	$ (7,319,669)	$ (11,800,274)
Weighted average number of common shares and equivalents:	22,614,248	21,807,634
Basic EPS	$ (0.32)	$ (0.54)
Diluted EPS	$ (0.32)	$ (0.54)

Net Loss Per Share (Schedule 66

Net Loss Per Share (Schedule Of Anti-Dilutive Securities Excluded From Computation Of Diluted Earnings Per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	79,410,284	78,138,047
Stock Options And Stock Appreciation Rights [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	413,301	671,887
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	39,537,501	37,335,618
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	680,363	1,167,099
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	38,779,119	38,963,443

Employee Benefit Plan (Details)

Employee Benefit Plan (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Empoyee Benefit Plan [Abstract]
Employer match of employee contributions	0.00%	0.00%

Product Warranty Provisions (De

Product Warranty Provisions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Product Warranty Provisions [Abstract]
Standard product warranty coverage term	1 year
Warranty accrual, beginning of the fiscal period	$ 222,845	$ 316,835
Accrual adjustment for product warranty	32,679	103,743
Payments made	(91,159)	(197,733)
Warranty accrual, end of the fiscal period	$ 164,365	$ 222,845

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($)	Sep. 29, 2016	Sep. 30, 2016	Dec. 31, 2016
Related Party Transaction [Line Items]
Proceeds from preferred stock and warrants issued, gross	$ 24,000,000
Preferred stock, shares issued	24,000
Common stock issuable from warrants	36,923,078
DAFNA Capital Management [Member]
Related Party Transaction [Line Items]
Legal fees related to stock issuance		$ 85,000
DAFNA Capital Management And Joe Kiani [Member]
Related Party Transaction [Line Items]
Legal fees related to stock issuance			$ 120,367
DAFNA Capital Management [Member] | Stereotaxis Inc. [Member]
Related Party Transaction [Line Items]
Ownership interest		5.00%

Segment Information (Details)

Segment Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Total revenue	$ 31,144,100	$ 32,164,116
Operating Segments [Member] | United States [Member]
Total revenue	18,038,638	19,420,815
Operating Segments [Member] | International [Member]
Total revenue	$ 13,105,462	$ 12,743,301

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	Mar. 05, 2018	Sep. 29, 2016	Sep. 26, 2016
Subsequent Event [Line Items]
Exercise price of warrants		$ 0.70	$ 0.70
Subsequent Event [Member]
Subsequent Event [Line Items]
Exercise price of warrants	$ 0.28
Number of warrants exercised	35,791,927
Proceeds from warrants	$ 10

Valuation And Qualifying Acco72

Valuation And Qualifying Accounts (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Allowance For Doubtful Accounts And Returns [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	$ 379,817	$ 93,478
Additions Charged to Cost and Expenses	(18,467)	292,690
Deductions	0	(6,351)
Balance at the End of Year	361,350	379,817
Allowance For Inventories Valuation [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	272,614	19,971
Additions Charged to Cost and Expenses	3,948,726	283,441
Deductions	(319,568)	(30,798)
Balance at the End of Year	$ 3,901,772	$ 272,614